Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics EVP and CFO Sung Lee received new equity awards. On 2026-03-15, Lee was granted 20,646 shares of Common Stock as an annual restricted stock unit award, increasing his direct holdings to 92,062 shares. He also received incentive and non-qualified stock options on 1,665 and 29,480 shares at an exercise price of $60.0600, vesting over four years.
Cytokinetics EVP of Research & Development Fady Ibraham Malik received new equity awards. On March 15, 2026, he was granted 27,306 shares of common stock as restricted stock units, increasing his direct common share holdings to 165,935.
He was also granted incentive stock options on 1,665 shares and non-qualified stock options on 39,527 shares, each with a $60.06 exercise price and expiring on March 14, 2036. The RSUs vest 40% after one year, 40% after two years, and 20% after three years, while the options vest in 48 equal monthly installments, all subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,709 shares of Common Stock in an open-market transaction at $61.03 per share. After this sale, he directly holds 46,149 shares, so the transaction represents a relatively small portion of his total reported holdings.
Andrew Callos reported multiple planned sales of Common Stock under a Rule 10b5-1 plan. The filing lists individual dispositions dated between 12/29/2025 and 03/09/2026, including transactions of 15,000 shares on 01/05/2026 and 15,000 shares on 02/05/2026, with listed proceeds for each trade. The transactions are described as 10b5-1 sales.
CYTOKINETICS INC executive Andrew Callos reported a small, tax-related stock sale. On the vesting of restricted stock units, he sold 2,582 shares of common stock on March 9, 2026 at $60.72 per share to satisfy company tax withholding obligations, and now directly holds 47,858 shares.
Cytokinetics EVP Research & Development Fady Ibraham Malik reported a small tax-related share sale. He sold 2,907 shares of Common Stock on March 9, 2026 in an open-market transaction at $60.72 per share.
According to the footnote, this was a sell-to-cover transaction to satisfy company tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale. After the transaction, he directly holds 138,629 shares of Cytokinetics common stock.
Cytokinetics President & CEO Robert I. Blum reported a small share sale primarily to cover tax obligations. On 2026-03-09, he sold 7,931 shares of common stock at $60.72 per share, described as a sell-to-cover transaction for company tax withholding on vested RSUs.
After this transaction, Blum directly holds 391,673 common shares, indicating the sale represents a minor portion of his direct stake. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC executive Andrew Callos, EVP and Chief Commercial Officer, reported multiple stock option exercises and related share sales. On March 5, 2026, he exercised two non-qualified stock options covering 11,000 and 15,000 shares, converting them into common stock through derivative exercises.
He then completed two open-market sales of common stock totaling 26,000 shares, with 15,000 shares sold at $61.87 per share and 11,000 shares sold at $61.88 per share. After these transactions, he held 50,440 shares of common stock directly. The reported stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued employment.
Cytokinetics Inc director Lynne Parshall reported an open-market sale of common stock. On March 2, 2026, she sold 5,000 shares at an average price of $61.21 per share. After this transaction, she directly owns 17,933 shares of Cytokinetics common stock.